Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
Xiangyan Li(Changchun University of Chinese Medicine), Wen‐Chin Huang(Cedars-Sinai Medical Center)
Cited by 74
Related Papers
Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells
|Molecular Cancer Research|2011|223
MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells
|PLoS ONE|2013|133
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer
|Oncotarget|2016|99
Androgen Receptor Survival Signaling Is Blocked by Anti-β2-microglobulin Monoclonal Antibody via a MAPK/Lipogenic Pathway in Human Prostate Cancer Cells
|Journal of Biological Chemistry|2010|54
β2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells
|Clinical Cancer Research|2008|42